Table 6.
Extended-Spectrum β-Lactamase-Producing Escherichia coli at Presentation and 21 days After Therapy
| Subjects and Timing | Subjects Positive for ESBL-Producing E. coli/Total No. (%) | |||
|---|---|---|---|---|
| Azithromycin | Levofloxacin | Rifaximin | Overall | |
| All subjects | ||||
| Day 0 | 6/71 (8.5) | 4/74 (5.4) | 1/72 (1.4) | 11/217 (5.1) |
| Day 21 | 5/57 (8.8) | 5/54 (9.3) | 5/44 (11.4) | 15/155 (9.7) |
| Subjects with paired samplesa | ||||
| Day 0 | 1/40 (2.5) | 2/37 (5.4) | 1/37 (2.7) | 4/114 (3.5) |
| Day 21 | 3/40 (7.5) | 3/37 (8.1) | 5/37 (13.5) | 11/114 (9.6) |
Abbreviation: ESBL, extended-spectrum β-lactamase.
aFor analysis of subjects with paired samples, day 21 data represent incident cases only (eg, excluding subjects who were positive for ESLB-producing E. coli on both day 0 and day 21).